Drugmaker Bristol Myers Squibb on Thursday said its second-quarter sales fell more than expected and cut its full-year forecast as two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition.
A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File photo2023 revenue seen falling slightly instead of risingon Thursday said its second-quarter sales fell more than expected and cut its full-year forecast as two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition.
It does not expect the increase in patients seeking free Revlimid and Pomalyst to continue to be a drag on sales next year, the company's executives said on a conference call.Bristol Myers is in the midst of a leadership change, with CEO Giovanni Caforio expected to step down in November to be succeeded by Chief Operating Officer Christopher Boerner.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Bristol Myers stock takes a hit from earnings miss and lower outlook amid disappointing Revlimid salesShares of Bristol Myers Squibb Co. shed 2.2% in premarket trading Thursday, after the drugmaker missed second-quarter earnings expectations and cut its...
Weiterlesen »
GSK raises 2023 earnings guidance on strong second-quarter salesGSK raised its full-year profit and sales guidance on Wednesday after its second-quarter earnings beat expectations, helped by strong sales of its shingles vaccine Shingrix and HIV medicines.
Weiterlesen »
Volkswagen All-Electric Car Sales Improved To Almost 95,000 In Q2 2023Volkswagen global all-electric car sales increased in Q2 2023, reaching roughly 94,800 units - nearly 52% more than a year ago.
Weiterlesen »
Audi Global All-Electric Car Sales Increased By 59% In Q2 2023In Q2, Audi global all-electric car sales amounted to roughly 41,100 BEVs, which is 59% more than a year ago, and a near record level.
Weiterlesen »
Cupra Born Sales Increased In Q2 2023 By 60% Year-Over-YearIn Q2, Seat/Cupra all-electric car sales amounted to 9,700 units, which is about 60% more than a year ago and more than 7% of the total volume.
Weiterlesen »
Skoda All-Electric Car Sales Reached a New Record In Q2 2023In Q2, Skoda noticeably increased its all-electric car sales - by 41% year-over-year to roughly 18,900 units - achieving the best quarterly result so far.
Weiterlesen »